Optimizing Bispecific Antibody Purification: Case Studies and Strategies
Bispecific and multispecific antibodies represent a rapidly growing class of therapeutics, distinguished by their ability to target multiple antigens simultaneously. However, their complex structures and diverse formats pose significant challenges to purification processes, particularly in achieving the high purity and safety standards required for clinical and commercial applications.
This webinar will explore the recent advancements in chromatography solutions and the latest strategies for optimizing the purification of bispecific antibodies, from initial capture to final polishing steps.
Join this webinar to discover:
- Techniques for effective capture and polish chromatography
- How to select the optimal affinity matrices for bispecific antibody purification
- Practical tips for overcoming specific challenges associated with advanced antibody formats
POROS: Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only. CaptureSelect: For Research Use or Further Manufacturing. Not for diagnostic use or direct administration in humans or animals.
Presenter: Robert Stairs (Field Applications Staff Scientist, Thermo Fisher Scientific)
Robert Stairs is a Field Applications Staff Scientist in the Bioproduction group at Thermo Fisher Scientific and is responsible for providing technical support for POROS and CaptureSelect chromatography resins. He has been a member of the team since 2023. Robert’s career began over 10 years ago as a part of the Preclinical Manufacturing and Process Development (PMPD) team at Regeneron Pharmaceuticals in Tarrytown, NY. In his role, he was responsible for early and late-stage downstream process development, characterization, scale-up, and technology transfer for monoclonal and bispecific antibody processes, with a specialization in polishing chromatography. Following that, Robert supported the process development team at Applied Genetic Technology Corporation (now Beacon Therapeutics) in Alachua, FL and was similarly responsible for downstream process development and technology transfer for AAV based gene therapy programs. Robert earned his Bachelor of Science in Bioengineering from the University of Maine in Orono, ME.
